Determinants of outcome in patients with sustained ventricular tachyarrhythmias: The Antiarrhythmics Versus Implantable Defibrillators (AVID) Study Registry

American Heart Journal

Volumn 139, Issue 5, 2000, Pages 804-813

  Pinski, Sergio L ^a   Yao, Qing ^j   Epstein, Andrew E ^b   Lancaster, Scott ^j   Greene, H Leon ^j   Pacifico, Antonio ^j   Cook, James R ^c   Jadonath, Ram ^j   Marinchak, Roger A ^j   Cooper, R A S ^b   Dailey, S M ^b   Kay, G N ^b   Plumb, V J ^b   Bubien, R S ^b   Knotts, S M ^b   McKenna, P T ^b   Greer, G S ^j   Santoro, I H ^j   Swaim, J ^j   Whittle, S ^j   Rizo Patron, C ^j   Belco, K M ^j   Payne, P ^j   Arnold, D J ^j   Zhu, W X ^j   Pratt, C M ^j   Kabell, G ^c   Kirchhoffer, J B ^c   Warwick, D ^c   Burkott, B ^c   Tomaszewski, D ^c   Podrid, P J ^j   Fuchs, T T ^j   Mazur, M ^j   Friedman, P L ^d   Stevenson, W G ^d   Swat, M M ^d   Ganz, L I ^d   Sweeney, M O ^d   Shea, J B ^d   Brodsky, M A ^e   Allen, B J ^e   Ehrlich, S S ^e   Wolff, L J ^e   Macari Hinson, M M ^e   Wise, G ^j   Duff, H ^j   Gillis, A ^j   Mitchell, B ^j   Rothschild, J ^j   Sheldon, R ^j   Cassidy, P ^j   Scheinman, M ^f   Eisenberg, S ^f   Epstein, L ^f   Fitzpatrick, A ^f   Griffin, G ^f   Lee, R ^f   Lesh, M ^f   Namekawa Wong, M ^f   Wong, M ^f   Wilkoff, B L ^j   Cross, J A ^j   Shewchik, J M ^j   Carlson, M D ^g   Rosenbaum, D S ^g   Lewis, W R ^g   Biblo, L A ^g   Mackall, J A ^g   Waldo, A L ^g   Coromilas, J ^h   Bigger Jr , J T ^h   Livelli Jr , F D ^h   Reiffel, J A ^h   Hickey, K ^h   Berns, E ^j   Lippman, N ^j   Barry, M B ^j   Carney, H M ^j   Russo, A M ^j   Waxman, H L ^j   Stubin, C A ^j   Morrissey, J M ^j   Raspa, D H ^j   Chilson, D A ^j   Lessmeier, T J ^j   Pochis, W T ^j   Baxter, J M ^j   Luceri, R M ^j   Zilo, P ^j   Weiss, D N ^j   Jonas, A ^j   Vardeman, L ^j   Schwartz, K M ^j   Asbell, C ^j   Curtis, A B ⁱ   Conti, J B ⁱ   Nelson, C ⁱ   Cannom, D S ^j   more..

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^h New York Presbyterian Hospital Columbia University Medical Center   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SOTALOL;

ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0034109306     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90011-5     Document Type: Article

References (48)

1. 1. Goldstein S, Landis JR, Leighton R, et al. Predictive survival models for resuscitated victims of out-of-hospital cardiac arrest with coronary heart disease. Circulation 1985;71:873-80.
2. 2. Willems AR, Tijssen JG, van Capelle FJ, et al. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction: the Dutch Ventricular Tachycardia Study Group of the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 1990;16:521-30.
3. 3. Trappe HJ, Brugada P, Talajic M, et al. Prognosis of patients with ventricular tachycardia and ventricular fibrillation: role of the underlying etiology. J Am Coll Cardiol 1988;12:166-74.
4. 4. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983;308:1436-42.
5. 5. Brugada P, Talajic M, Smeets J, et al. The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Eur Heart J 1989;10:74752.
6. 6. Gomes JA, Mehta D, Ip J, et al. Predictors of long-term survival in patients with malignant ventricular arrhythmias. Am J Cardiol 1997;79:1054-60.
7. 7. Lampert S, Lown B, Graboys TB, et al. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease. Am J Cardiol 1988;61:791-7.
8. 8. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988;318:19-24.
9. 9. Furukawa T, Rozanski JJ, Nogami A, et al. Time-dependent risk and predictors of cardiac arrest recurrence in survivors of out-of-hospital cardiac arrest with chronic coronary artery disease. Circulation 1989;80:599-608.
10. 10. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
11. 11. Wever EFD, Hauer RNW, van Capelle PJL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation 1995;91:2195-203.
12. 12. Saksena S, Madan N, Lewis C. Implantable cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Prog Cardiovasc Dis 1996;38:445-54.
13. 13. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 1997;96:1525-31.
14. 14. CASCADE Investigators. Cardiac Arrest in Seattle: Conventional versus Amiodarone Drug Evaluation (the CASCADE Study). Am J Cardiol 1991;67:578-84.
15. 15. Mason JW, for the ESVEM Investigators. A comparison of 7 antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
16. 16. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
17. 17. Hjalmarson A, Kneider M, Waagstein F. The role of beta-blockers in left ventricular dysfunction and heart failure. Drugs 1997;54:501-10.
18. 18. Hennekens CH. Aspirin in the treatment and prevention of cardiovascular disease. Annu Rev Public Health 1997;18:37-49.
19. 19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
20. 20. Baker DW, Jones R, Hodges J, et al. Management of heart failure, III: the role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528-34.
21. 21. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-20.
22. 22. Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
23. 23. Anderson JL, Hallstrom AP, Epstein AE, et al. Design and results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry. Circulation 1999;99:1692-9.
24. 24. Lehman MH, Steinman RT, Meissner MD, et al. Need for a standardized approach to grading symptoms associated with ventricular tachyarrhythmias. Am J Cardiol 1991;67:421-3.
25. 25. Pinski SL, Sgarbossa EB, Trohman RG, et al. Selection bias in electrophysiologically guided therapy of sustained ventricular tachyarrhythmias. J Clin Epidemiol 1994;47:49-57.
26. 26. Pinski SL, Maloney JD, Sgarbossa EB, et al. Survival after a first episode of ventricular tachycardia or fibrillation. Pacing Clin Electrophysiol 1992;15:2169-73.
27. 27. Pinski SL, Page RL, Mounsey JP, et al. Absence of prevalence-incidence bias in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial [abstract]. J Am Coll Cardiol 1998;31:121A.
28. 28. Hood WB Jr, Youngblood M, Ghali JK, et al. Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1991;68:1465-8.
29. 29. Landolina M, Mantica M, Pessano P, et al. Impaired baroreflex sensitivity is correlated with hemodynamic deterioration of sustained ventricular tachycardia. J Am Coll Cardiol 1997;29:568-75.
30. 30. Ellenbogen KA, Smith ML, Thames MD, et al. Changes in regional adrenergic tone during sustained ventricular tachycardia associated with coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1990;65:1334-8.
31. 31. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986;314:271-5.
32. 32. Adhar GC, Larson LW, Bardy GH, et al. Sustained ventricular arrhythmias: differences between survivors of cardiac arrest and patients with recurrent sustained ventricular tachycardia. J Am Coll Cardiol 1988;12:159-65.
33. 33. Stevenson WG, Brugada P, Waldecker B, et al. Clinical, angiographic, and electrophysiologic findings in patients with aborted sudden death as compared with patients with sustained ventricular tachycardia after myocardial infarction. Circulation 1985;76: 1146-52.
34. 34. Marchlinski FE. Predicting arrhythmic death: a plea for standardized reporting techniques and data based on continuous electrocardiographic monitoring. Circulation 1997;96:1713-6.
35. 35. Sarter BH, Finkle JK, Gerszten RE, et al. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996;28:122-9.
36. 36. Pratt CM, Greenwy PS, Schoenfeld MH, et al. Exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996;93:519-24.
37. 37. Epstein AE, Carlson MD, Fogoros RN, et al. Classification of death in arrhythmia trials. J Am Coll Cardiol 1996;27:433-42.
38. 38. Ziesche S, Rector TS, Cohn JN. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. J Card Fail 1995;1:127-32.
39. 39. Caruso AC, Marcus FI, Hahn EA, et al. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial: Electrophysiologic Study Versus Electrocardiographic Monitoring. Circulation 1997; 96:1888-92
40. 40. Menz V, Schwartzman D, Nallamothu N, et al. Does the initial presentation of patients with implantable defibrillator influence the outcome? Pacing Clin Electrophysiol 1997;20:173-6.
41. 41. Wilber DJ, Davis MJ, Rosenbaum M, et al. Incidence and determinants of multiple morphologically distinct sustained ventricular tachycardias. J Am Coll Cardiol 1987;10:583-91.
42. 42. Trappe HJ, Brugada P, Talajic M, et al. Value of induction of pleomorphic ventricular tachycardia programmed stimulation. Eur Heart J 1989;10:133-41.
43. 43. Böcker D, Block M, Isbruch F, et al. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia. Br Heart J 1995;73:158-63.
44. 44. Roitt M, Klein RC, Greene LH, et al. Arrhythmia recurrence in patients presenting with ventricular fibrillation compared to ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillator (AVID) trial [abstract]. J Am Coll Cardiol 1999;98:1-495.
45. 45. Roden M. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331:785-91.
46. 46. Kim SG, Fogoros RN, Furman S, et al. Standardized reporting of ICD patient outcome: the report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993. Pacing Clin Electrophysiol 1993;16:1358-62.
47. 47. Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995;92:1651-64.
48. 48. Klein RC, Belco K, Yao Q, et al. Crossover to unassigned therapy among patients in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial [abstract]. Pacing Clin Electrophysiol 1998; 21:826.